Clarivate Plc(NYSE) CLVT

Clarivate Plc helps people find and protect new ideas. It provides data to researchers, lawyers, and drug makers. These tools turn complex information into useful insights.

Tools for the Innovation Lifecycle

• Academia and Government: Platforms like Web of Science and EndNote for research and funding; supports organizations throughout the entire research lifecycle.
• Intellectual Property: Management tools including Derwent Innovation and CompuMark; helps legal firms and businesses protect patents and trademarks.
• Life Sciences and Healthcare: Intelligence solutions like Cortellis and Newport Integrity; assists pharmaceutical companies in drug development and market monitoring.

A Strategic Shift in Focus

• Announced a definitive agreement to sell the Life Sciences and Healthcare business in July 2026.
• Launched the Value Creation Plan in late 2024 to restructure operations and improve efficiency.
• Approved the wind-down of three specific product groups in December 2024 to simplify the portfolio.
• Repurchased and retired $117.6 million in debt during the first six months of 2026.

What Makes Clarivate Different?

The company relies on a subscription model that creates predictable cash flows through multiyear contracts. Its business uses specialized databases and expert-curated content to provide insights that are difficult to replicate.

The Latest Financial Results

• Revenue was $587.3 million in the three months ended June 30, 2026, down 5% year over year.
• Net loss was $268.6 million in the three months ended June 30, 2026.
• Free cash flow was $122.9 million for the six-month period ended June 30, 2026, down 23% year over year.
• Annual renewal rate for subscription agreements was 91.9% as of June 30, 2026.

Evolution Toward a Leaner Model

Clarivate is shifting its focus by divesting its healthcare unit to streamline its intelligence portfolio. This transition aims to improve operational efficiency while maintaining stable renewal rates in its core research segments.